Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): a prospective phase 2/3 trial of MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches using ctDNA status as a surrogate for MRD status (NRG-GI008) (NCT05174169).
Currently, determination of whether adjuvant chemotherapy is required for colon cancer is based on tumor/node/metastasis staging and clinical and pathological factors. However, the absolute benefit of adjuvant therapy for stage II and III colon cancer is ~5% and ~25% to 30%, respectively, indicating that the benefit is limited to a subgroup of patients with colon cancer. Therefore, more precise approaches to defining patients at risk for recurrence are required.
The detection of circulating tumor DNA (ctDNA) in blood samples has evolved significantly over the past decade, and studies have investigated the clinical and prognostic value of ctDNA in early-stage colon cancer. Recent studies identified ctDNA status as one of the most powerful prognostic factors and a surrogate for minimal residual disease (MRD) for patients with early-stage colon cancer. However, at this time, the clinical use of ctDNA for the determination of adjuvant therapy is not well established and represents an unmet need for research. CIRCULATE-US, a prospective phase 2/3 trial, will be investigating MRD-based adjuvant therapy for patients with early-stage colon cancer with intensified and deintensified adjuvant therapy approaches by using ctDNA status as a surrogate for MRD status. This trial will use Signatera ctDNA testing to determine the ctDNA status of patients entering the study.
Patients with confirmed stage IIIA or stage IIIB mismatch repair–proficient colon adenocarcinoma (T1-3, N1/N1c) will be included in this study. Patients with T4 or N2 disease will be excluded from cohort A to exclude the potential negative impact of a possible false-negative result of ctDNA testing on the survival of patients. Patients who have positive ctDNA results from commercially obtained Signatera testing and stage II and IIIC colon adenocarcinoma and who otherwise meet the rest of the eligibility criteria can be enrolled in cohort B. Eligible patients will have adequate organ function and a baseline radiologic exam within 28 days before enrollment without evidence of metastatic disease. Patients with mismatch repair–deficient colon cancer, tumor-related bowel perforation, or distal tumor extension of 12 cm or less will be excluded from this study.
Study sites: The study is activated across the National Cancer Institute’s National Clinical Trials Network.
Primary Investigator:
Arvind Dasari, MD, MS
Gastrointestinal Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
ADasari@mdanderson.org
Co-Primary Investigator:
Christopher Lieu, MD
Medical Oncology
University of Colorado Cancer Center
Aurora, CO
christopher.lieu@cuanschutz.edu
Phone: +81 4 7133 1111
Fax: +81 4 7134 6928
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.